These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33622266)

  • 21. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.
    Scheiner B; Mandorfer M; Schwabl P; Payer BA; Bucsics T; Bota S; Aichelburg MC; Grabmeier-Pfistershammer K; Stättermayer A; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
    PLoS One; 2015; 10(11):e0143429. PubMed ID: 26599080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C.
    Magri MC; Alvarez MSM; Iogi AA; Alves GM; Manchiero C; Dantas BP; Prata TVG; Nunes AKDS; Tengan FM
    Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33476381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.
    Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Cirillo G; Grandone A; Salpietro S; Minichini C; Del Giudice EM; Lazzarin A; Sagnelli E; Coppola N
    Clin Microbiol Infect; 2016 Apr; 22(4):372-378. PubMed ID: 26806136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
    Senkerikova R; Frankova S; Jirsa M; Kreidlova M; Merta D; Neroldova M; Chmelova K; Spicak J; Sperl J
    PLoS One; 2019; 14(9):e0222609. PubMed ID: 31527889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.
    Chuaypen N; Siripongsakun S; Hiranrat P; Tanpowpong N; Avihingsanon A; Tangkijvanich P
    PLoS One; 2022; 17(6):e0269641. PubMed ID: 35696400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
    Raksayot M; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Treeprasertsuk S; Poovorawan Y; Tanaka Y; Tangkijvanich P
    J Gastroenterol; 2019 May; 54(5):427-436. PubMed ID: 30506232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
    Cavalcante LN; Porto J; Mazo D; Longatto-Filho A; Stefano JT; Lyra AC; Carrilho FJ; Reis RM; Alves VAF; Sanyal AJ; Oliveira CP
    Ann Hepatol; 2022; 27(6):100728. PubMed ID: 35710086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.
    Liu ZT; Chen TC; Lu XX; Cheng J; Xie HY; Zhou L; Zheng SS
    World J Gastroenterol; 2015 Sep; 21(34):10054-6. PubMed ID: 26379412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis.
    Israelsen M; Juel HB; Detlefsen S; Madsen BS; Rasmussen DN; Larsen TR; Kjærgaard M; Fernandes Jensen MJ; Stender S; Hansen T; Krag A; Thiele M;
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1784-1794.e9. PubMed ID: 33279778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
    Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
    World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?
    Machado CM; Leite NC; França PH; Cardoso CR; Salles GF; Villela-Nogueira CA
    Nutr Metab Cardiovasc Dis; 2019 Sep; 29(9):965-971. PubMed ID: 31377187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOC3rs2854116, PNPLA3rs738409, and TM6SF2rs58542926 polymorphisms might influence predisposition of NAFLD: A meta-analysis.
    Tong M; Wang F
    IUBMB Life; 2020 Aug; 72(8):1757-1764. PubMed ID: 32525256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
    Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of genetic variants, genetic risk score and DNA methylation of PNPLA3 and TM6SF2 in alcohol liver cirrhosis.
    Shankarappa B; Mahadevan J; Murthy P; Purushottam M; Viswanath B; Jain S; Devarbhavi H; Mysore V A
    Indian J Gastroenterol; 2023 Dec; 42(6):800-807. PubMed ID: 37589914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response.
    Gavril OI; Arhire LI; Gavrilescu O; Dranga M; Barboi O; Gavril RS; Popescu R; Cijevschi Prelipcean C; Trifan AV; Mihai C
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833371
    [No Abstract]   [Full Text] [Related]  

  • 39. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.